A review of the potential uses for recombinant human TSH in patients with thyroid cancer and nodular goiter

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Clinical Endocrinology

• Publication date

  2004-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2265.2004.02025.xPMID 15272910
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes.

  2006cited by this paper
• Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma.

  2004cited by this paper
• Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter.

  2003cited by this paper
• Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.

  2003cited by this paper
• Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease

  2003cited by this paper
• Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.

  2003cited by this paper
• Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter.

  2003cited by this paper
• Recombinant human TSH testing is a valuable tool for differential diagnosis of congenital hypothyroidism during l‐thyroxine replacement

  2003cited by this paper
• A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.

  2003influential reference
• Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters.

  2003cited by this paper
• Management of Low-Risk Well-Differentiated Thyroid Cancer Based Only on Thyroglobulin Measurement After Recombinant Human Thyrotropin

  2002cited by this paper
• The use of recombinant human TSH in the follow‐up of differentiated thyroid cancer: experience from a large patient cohort in a single centre

  2002cited by this paper
• Clinical Comparison of Whole-Body Radioiodine Scan and Serum Thyroglobulin After Stimulation with Recombinant Human Thyrotropin

  2002cited by this paper
• Influence of rhTSH on [18F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma

  2002cited by this paper
• Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.

  2002cited by this paper
• Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer.

  2002cited by this paper
• A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.

  2002cited by this paper
• Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone

  2002cited by this paper
• Better Yield of 18Fluorodeoxyglucose-Positron Emission Tomography in Patients with Metastatic Differentiated Thyroid Carcinoma during Thyrotropin Stimulation

  2002cited by this paper
• Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.

  2002cited by this paper
• Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?

  2002cited by this paper
• Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?

  2002cited by this paper
• Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma.

  2002cited by this paper
• Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer.

  2001cited by this paper
• Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters.

  2001cited by this paper
• Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects.

  2001cited by this paper
• Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma.

  2001cited by this paper
• The effect of recombinant human tsh on the thyroid (123)i uptake in iodide treated normal subjects.

  2001cited by this paper
• Usefulness of Recombinant Human Thyrotropin in the Radiometabolic Treatment of Selected Patients with Thyroid Cancer

  2001cited by this paper
• Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.

  2001cited by this paper
• Radioiodine Ablation of Thyroid Remnants After Preparation with Recombinant Human Thyrotropin

  2001cited by this paper
• Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.

  2001cited by this paper
• Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.

  2001cited by this paper
• Clinical Experience with Recombinant Human Thyrotrophin (rhTSH) in the Management of Patients with Differentiated Thyroid Cancer

  2000cited by this paper
• The use of recombinant human TSH in a patient with metastatic follicular carcinoma and insufficient endogenous TSH production

  2000cited by this paper
• Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma.

  2000cited by this paper
• Mapping Sentinel Lymph Node in Breast Cancer by Combined Lymphoscintigraphy, Blue-Dye, and Intraoperative Gamma-Probe

  2000cited by this paper
• Administration of a single low dose of recombinant human thyrotropin significantly enhances thyroid radioiodide uptake in nontoxic nodular goiter.

  2000cited by this paper
• Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature.

  2000cited by this paper
• Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.

  2000cited by this paper
• Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?

  2000cited by this paper
• A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.

  1999cited by this paper
• Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain.

  1999cited by this paper
• Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience.

  1999cited by this paper
• Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): whole-body scanning with iodine-131.

  1999cited by this paper
• Recombinant Human Thyrotropin in Thyroid Cancer and Hypopituitarism Due to Sella Metastasis

  1999cited by this paper
• Management of the patient with progressive radioiodine non-responsive disease.

  1999cited by this paper
• Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): serum thyroglobulin measurement.

  1999cited by this paper
• Isolated Thyrotropin Deficiency Secondary to Primary Empty Sella in a Patient with Differentiated Thyroid Carcinoma: An Indication for Recombinant Thyrotropin

  1999cited by this paper
• The Effect of Recombinant Human Thyrotropin (rhTSH) on Thyroid Function in Mice and Rats

  1998cited by this paper
• Recombinant human thyrotropin is a potent stimulator of thyroid function in normal subjects.

  1997cited by this paper
• Quality-of-Life Changes in Patients with Thyroid Cancer After Withdrawal of Thyroid Hormone Therapy

  1997cited by this paper
• Radioiodine for Nontoxic Multinodular Goiter

  1997cited by this paper
• Prognosis and treatment of brain metastases in thyroid carcinoma.

  1997cited by this paper
• Treatment of Scan-Negative, Thyroglobulin-Positive Metastatic Thyroid Cancer Using Radioiodine 131I and Recombinant Human Thyroid Stimulating Hormone

  1997cited by this paper
• Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone.

  1997cited by this paper
• Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma.

  1997cited by this paper
• Improvement of upper airway obstruction after 131I-treatment of multinodular nontoxic goiter evaluated by flow volume loop curves

  1996cited by this paper
• Diagnostic accuracy of 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism.

  1996cited by this paper
• Reduction in goiter size by 131I therapy in patients with non-toxic multinodular goiter.

  1995cited by this paper
• Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).

  1994cited by this paper
• Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.

  1994cited by this paper
• Large, Compressive Goiters Treated with Radioiodine

  1994cited by this paper
• Radioiodine treatment of multinodular non-toxic goitre.

  1993cited by this paper
• The regulation of two distinct glucose transporter (GLUT1 and GLUT4) gene expressions in cultured rat thyroid cells by thyrotropin.

  1992cited by this paper
• Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells.

  1991cited by this paper
• Recombinant human thyroid-stimulating hormone: initial bioactivity assessment using human fetal thyroid cells.

  1991cited by this paper
• Radioiodine therapy in voluminous multinodular non-toxic goitre.

  1990cited by this paper
• The Human Thyrotropin β-Subunit Gene Differs in 5′ Structure from Murine TSH-β Genes

  1988cited by this paper
• The human thyrotropin beta-subunit gene differs in 5' structure from murine TSH-beta genes.

  1988cited by this paper
• Isolation and characterization of the human thyrotropin beta-subunit gene. Differences in gene structure and promoter function from murine species.

  1988cited by this paper
• Treatment of non-toxic multinodular goiter with radioactive iodine.

  1988cited by this paper
• Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre.

  1988cited by this paper
• Cloning of the human thyrotropin beta-subunit gene and transient expression of biologically active human thyrotropin after gene transfection.

  1988cited by this paper
• Thyrotropin stimulates glucose transport in cultured rat thyroid cells.

  1987cited by this paper

• The EANM guideline on radioiodine therapy of benign thyroid disease

  2023cites this paper
• Multidisciplinary Diagnosis of Subcutaneous Soft Tissue Metastasis of Follicular Thyroid Carcinoma: A Case Report

  2020cites this paper
• Surveillance for Differentiated Thyroid Cancer Recurrence.

  2019cites this paper
• Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma

  2017cites this paper
• An Enantiomer of an Oral Small-Molecule TSH Receptor Agonist Exhibits Improved Pharmacologic Properties

  2016cites this paper
• CHAPTER 19 – Thyroid dysfunction

  2014cites this paper
• The role of radioiodine therapy in benign nodular goitre.

  2014cites this paper
• Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome.

  2012cites this paper
• Update in TSH receptor agonists and antagonists.

  2012cites this paper
• Pharmacodynamic Evaluation: Endocrinology

  2011cites this paper
• Effect of recombinant human TSH on the uptake of radioactive iodine ((123)I) by the thyroid gland in healthy beagles.

  2010cites this paper
• DISORDERS OF THE HYPOTHALAMIC-PITUITARY AXIS

  2009cites this paper
• Radioiodine - an attractive alternative to surgery in large non-toxic multinodular goitres.

  2009cites this paper
• Review on the Occasion of a Decade of Recombinant Human TSH: Prospects and Novel Uses

  2008cites this paper
• Presence of a functional TSH receptor on human erythrocytes.

  2007cites this paper
• [Sodium iodide symporter in physiology and diseases -- the current state of knowledge].

  2007cites this paper
• Peripheral blood levels of thyroglobulin mRNA and serum thyroglobulin concentrations after radioiodine ablation of multinodular goiter with or without pre-treatment with recombinant human thyrotropin

  2007cites this paper
• Abagyan R., Totrov M., Kuznetsov D. ICM-A new Method for protein Modeling and Design.Applications to Docking and structure Prediction from the Distorded native Conformation. 1994 J. Comp. Chem. 15, 488-506

  2007cites this paper
• Concordancia analítica de la tiroglobulina estimulada con tirotropina recombinante humana y tras privación hormonal previa a la terapia con 131I en pacientes con cáncer diferenciado de tiroides

  2007cites this paper
• Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when.

  2007cites this paper
• La TSH recombinante : son utilisation en Endocrinologie

  2006cites this paper
• Recombinant Human Thyrotropin-Assisted Radioiodine Therapy for Patients with Metastatic Thyroid Cancer Who Could Not Elevate Endogenous Thyrotropin or Be Withdrawn from Thyroxine

  2006cites this paper
• Use of recombinant human thyroid-stimulating hormone in the management of well-differentiated thyroid cancer

  2006cites this paper
• A Low Molecular Weight Agonist Signals by Binding to the Transmembrane Domain of Thyroid-stimulating Hormone Receptor (TSHR) and Luteinizing Hormone/Chorionic Gonadotropin Receptor (LHCGR)*

  2006cites this paper
• Detection and Surgical Treatment of Cervical Lymph Nodes in Differentiated Thyroid Cancer

  2006cites this paper
• Thyroid Remnant Radioiodine Ablation with Recombinant Human Thyrotropin

  2006cites this paper
• What is the contribution of a kozak snp in the CD40 gene to graves’ disease?

  2005cites this paper
• Duration of Preparation for Postoperative Radioiodine Administration in Differentiated Thyroid Carcinoma

  2005cites this paper
• Clinical application of rhTSH in differentiated thyroid cancer: the facts and the questions

  2005cites this paper
• Actualización del tratamiento con radioyodo: utilidad de la TSH humana recombinante

  2005cites this paper
• Disease Thyroglobulin : a thyroid autoantigen and marker of DTC

  2005cites this paper
• Clinical uses of recombinant human thyrotropin

  2004cites this paper
• Index

  2004cites this paper